Solventum Corporation (NYSE:SOLV) Receives $91.64 Average Target Price from Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $91.6364.

A number of research analysts have recently issued reports on the company. Piper Sandler upped their price target on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. BMO Capital Markets began coverage on Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. BTIG Research lifted their price objective on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings raised Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, August 22nd.

Solventum Price Performance

Shares of SOLV opened at $91.70 on Wednesday. The company has a market capitalization of $15.61 billion, a P/E ratio of 11.21, a price-to-earnings-growth ratio of 1.44 and a beta of 0.61. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $84.00 and a 200 day moving average of $76.01. Solventum has a twelve month low of $62.38 and a twelve month high of $94.16.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same period in the prior year, the firm posted $1.69 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities research analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SOLV. CrossGen Wealth LLC bought a new stake in Solventum in the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC bought a new position in shares of Solventum during the 3rd quarter valued at $25,000. Clearstead Trust LLC lifted its holdings in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares during the period. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum in the 2nd quarter worth $28,000. Finally, Modus Advisors LLC purchased a new position in shares of Solventum in the 4th quarter worth $30,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.